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Abstract: The ABCB1 gene encodes the P-glycoprotein (Pgp) protein, which is thought to 
transport various antiepileptic drugs. The single nucleotide polymorphism (SNP) (C3435T) in 
exon 26 of this gene correlates with the altered expression levels of P-glycoprotein, range of drug 
response and clinical conditions. In order to investigate the influence of this polymorphism on the 
susceptibility to and efficacy of carbamazepine therapy, we evaluated the allelic frequency and 
genotype distribution of this variant in 162 epilepsy patients from the Republic of Macedonia. 
Statistically significant differences were detected neither in the allelic frequency and genotype 
distribution between carbamazepine-resistant and carbamazepine-responsive epilepsy patients 
nor between the subgroups of carbamazepine (CBZ)-responsive patients treated with different 
CBZ doses. However, the T-allele was enriched in CBZ-responsive patients who required higher 
maintenance CBZ doses, This observation was substantiated by the findings that the median 
total plasma levels were the lowest in patients with CC (20 µmol/L) followed by CT (23 µmol/L) 
and TT (29 µmol/L) genotypes. Patients with a CC genotype also had a higher likelihood of 
response compared to patients with CT or TT genotypes over a wide range (400–1000 mg/day) 
of initial doses of CBZ. The T allele showed a reduced expression of ∼5% compared to the C 
allele in peripheral blood mononuclear cells in heterozygotes for the variant. This difference 
might be translated into ∼10% difference in homozygotes for the variant, which would explain 
the trend towards a dose-dependent efficacy of the CBZ treatment in patients with different 
genotypes. A larger prospective study is warranted to clarify the clinical utility of a genotype-
specific individualized CBZ therapy.
Keywords: multidrug resistance protein 1 (MDR1), ABCB1 C3435T polymorphism, epilepsy 
treatment, carbamazepine
Introduction
The ABCB1 gene (also known as multidrug resistance protein 1-MDR1), is potentially 
an important candidate gene influencing the response to antiepileptic drugs (AEDs). 
This gene encodes P-glycoprotein (Pgp), which is thought to transport various anti-
epileptic drugs.1   Carbamazepine (CBZ) is a lipophilic agent and thus a theoretical 
substrate for Pgp, but the scientific evidence is still equivocal.2–5 Pgp takes part in 
the energy-dependent export of substances from the inside of cells, as well as from 
membranes, to the outside. Pgp is expressed in tissues with excretory functions (eg, 
the small intestine, liver, and kidney), and at blood–tissue barriers (eg, the blood–brain 
barrier [BBB], the blood–testis barrier and the placenta), thus limiting drug entry 
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into body tissues after oral administration, promoting drug 
elimination into bile and urine, and limiting drug penetration 
into sensitive tissues such as the brain.6
The single nucleotide polymorphism (SNP) C3435T in 
exon 26 is one of more than 100 polymorphic variants of this 
gene that have been discovered to date.7 This polymorphism 
correlates with altered expression levels of P-glycoprotein, 
range of drug response and clinical conditions.8 However, 
the nature of this relationship is still unclear.
Some of the published studies have documented an 
association of pharmaceutical resistance with the 3435CC 
genotype of the MDR1/ABCB1 gene9–11 whereas other stud-
ies were unable to identify any association.12,13 In addition, 
several studies have shown that the CC genotype is associ-
ated with increased expression of Pgp in the brain, liver, 
and duodenum.
The present study investigates the influence of the ABCB1 
C3435CT SNP on the efficacy of carbamazepine therapy in 
patients with epilepsy from the Republic of Macedonia.
Materials and methods
In this study, 162 adult patients of both sexes (76 males and 
86 females, average age 53 ± 15.5) from the Republic of 
Macedonia, all of them with normal renal and hepatic function, 
were treated with a carbamazepine monotherapy for at least 
2 years. The type of seizures and epileptic syndrome were classi-
fied according to the ILAE classification (Table 1). The participa-
tion of each subject was voluntary and could be cancelled by 
any individual at any time during this study (according to the 
Helsinki II declaration). The Ethics Committees of the Faculty 
of Pharmacy and Faculty of Medicine, St Cyril and Methodius 
University, Skopje, approved the research protocol for this 
study and all volunteers signed the informed consent form.
Genomic DNA was extracted from whole blood, using 
a QIAGEN DNA extraction kit and the procedure recom-
mended by the manufacturer (QIAGEN AS, Oslo, Norway). 
The presence of the ABCB1 C3435T polymorphism (rs 
1045642) was analyzed by the allelic discrimination TaqMan 
assay (MxPro 3005P, Strategene, La Jolla, CA) according to 
the manufacturer’s instructions (Applied Biosystems, Foster 
City, CA).
The relative level of expression of C versus T allele of the 
variant in peripheral blood mononuclear cells (PBMC) was 
performed using a RFLP based quantitative PCR method, 
as described in details previously.14 Briefly, total RNA was 
isolated from peripheral blood mononuclear cells of 25 
heterozygotes (15 patients and 10 controls), 5 homozygotes, 
each for the C and the T alleles, using the QIAGEN RNA 
blood extraction kit (QIAGEN AS, Oslo, Norway). Three 
microliters of these RNA samples was reversely transcribed 
into cDNA and subsequently amplified for 35 cycles (95°C 
for 1 minute, 60°C for 1 minute, and 72°C for 1.5 minutes) 
using two primers (ABCB1 Eg25 Dir 5′-AAG AGC ACA 
GTG GTC CAG CTC C-3′ and ABCB1 Eg27 Rev 5′-ACG 
AGC TAT GGC AAt GCS TTG-3′) located in the flank-
ing exon 26 where the ABCB1 3435 C-T polymorphism 
resides. Five microliters of this reaction was subjected to 
one cycle of primer extension using 100 pM of 5′ FAM 
labeled primer ABCB1 Eg25 Dir/FAM 5′- AAG AGC ACA 
GTG GTC CAG CTC C-3′ (95°C for 15 minutes, 60°C for 
2 minutes, and 72°C for 10 minutes). The resulting labeled 
339 bp fragment was digested with 0.5 µL MboI restriction 
enzyme at 37°C for 12 hours. MboI cuts the PCR fragment from 
the C-allele into two fragments of 206 and 133 bp, whereas 
the PCR fragments from the T-allele remain   undigested. 
The digestion products were separated with capillary   
Table 1 Characteristics of patients
No Sex Age Cryptogenic  
partial epilepsy
Symptomatic  
partial epilepsy
Generalized  
epilepsy
Other  
etiology
Epilepsy patients 162 76 (M) and 86 (F) 15–77 
53 ± 14.5
118 35 7 2
CBZ-resistant patients 68 35 (M) and 33 (F) 53 11 3 1
CBZ-responder patients 94 41 (M) and 53 (F) 65 24 4 1
Abbreviation: CBZ, carbamazepine.
Table 2 Allele and genotype distribution in epilepsy patients from the Republic of Macedonia
Allele Adjuster OR  
95% CI
P-value Genotype Adjuster OR  
95% CI
P-value
C T CC CT TT
CBZ-responsive  
patients
95 (0.51) 93 (0.49) 1.052 
0.677-1.636
0.82187 25 (0.27) 45 (0.53) 24 (0.20) 1,116 
0.445–2.797
0.81476
CBZ-resistant  
patients
69 (0.51) 67 (0.49) 0.951 
0.611–1.478
15 (0.22) 39 (0.57) 14 (0.21) 0896 
0.357–2.246
Abbreviations: CBZ, carbamazepine; CI, confidence interval; OR, odds ratio.
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electrophoresis on an ABI 310 Genetic Analyzer (Applied 
Biosystems, Carlsbad, CA) and the relative quantities of the 
339 bp fragment (T-allele) and 206 bp fragment (C-allele) 
in heterozygotes were determined using the GeneMapper® 
software 4.0 (Applied Biosystems). The samples from 
homozygotes for the T and C alleles were used as controls 
for specificity and completeness of the enzymatic digestion, 
respectively.
Plasma CBZ concentrations were measured using the 
fluorescence polarization immunoassay (TDx/FLx system, 
Abbott Laboratories, Abbott Park, IL) and HPLC method. 
For the HPLC method, the separation was carried out on 
a Waters HPLC system (Waters Corporation, Milford, 
MA) with a reversed-phase column (Zorbax Extend C18, 
150 × 4.6 mm, 5 µm; Agilent Technologies, Colorado 
Springs, CO) using isocratic elution with acetonitrile and 
water (35:65) as a mobile phase. The temperature was 
30°C and UV detection was set at 220 nm. Method valida-
tion was developed   following the recommendations for 
validation of bioanalytical methods of EMA guideline. 
The preparation of samples was based on the solid-phase 
extraction. The plasma from epileptic patients was spiked 
with 100 µL IS, while the blank plasma was previously 
spiked with CBZ standard for analyses. The mixture was 
vortex-mixed for 30 seconds and loaded into Oasis HLB 
cartridges (Waters Corporation, Milford, MA) previously 
conditioned with 1 mL methanol/water. This was followed 
by washing with 1 mL 5% methanol and elution with 1 mL 
of absolute methanol.
For the purpose of our investigation, we proposed the 
following working definitions:
•  individual therapeutic dose: a dose of a given drug 
which has not been changed for two or more consecutive 
visits in the history of the patient’s treatment.
•  drug responsiveness: a completely seizure-free condi-
tion for at least 1 year during treatment with CBZ.
•  drug resistance: the occurrence of at least four seizures 
over a period of 1 year during treatment with CBZ.
The Hardy–Weinberg equilibrium (HWE) for ABCB1 
C3435T SNP was determined using an online calculator 
(http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl). 
The descriptive statistical analysis was done using the 
GraphPad Prism version 5.00 for Windows (GraphPad 
Software Inc, La Jolla, CA). Kruskal–Wallis and Mann–
Whitney tests (P , 0.05) were used to compare the CBZ 
responsiveness doses between patients with different 
genotypes.
Results
The CC, CT, and TT genotypes were identified in 162 patients. 
No statistically significant differences were found in the 
allelic frequency and genotype distribution between CBZ-
resistant and CBZ-responsive epilepsy patients. The distribu-
tion of all genotype frequencies did not deviate significantly 
from Hardy–Weinberg expectations (Table 2).
The results showed that CBZ-responsive patients with 
a TT genotype need a higher average maintenance dose 
of carbamazepine as a monotherapy (650 ± 343 mg/day) 
in comparison with patients with CC and CT genotypes 
(387 ± 217 mg/day and 548 ± 204 mg/day respectively). The 
values for median of CBZ doses were: 400 mg CBZ/day for 
TT, 600 mg CBZ/day for CT and 400 mg CBZ/day for CC 
genotypes (Figure 1). The differences in doses among patients 
CC
CT
TT
Genotype
200
600
C
B
Z
 
d
o
s
e
 
i
n
 
m
i
l
l
i
g
r
a
m
s
1000
1400
1200
800
400
0
Figure 1 Distribution of CBZ dose in mg among different genotypes.
Abbreviation: CBZ, carbamazepine.
Table 3 Distribution of CBZ dose among CBZ-responsive patients with different genotypes from the Republic of Macedonia
200 400 600 800 1000 1200 Total Mann–Whitney test
CC/CT CT/TT CC/TT CC + CT/TT CC/CT+TT
CC 4 13 2 3 0 2 24
CT 1 19 13 10 1 1 45 P = 0.0957 P = 0.8717 P = 0.1820 P = 0.7644 P = 0.4473
TT 2 11 2 6 1 3 25 U = 434 U = 549.5 U = 247.5 U = 263.5 U = 293.0
Total 7 43 17 19 2 6 94
Note: CC/CT/TT Kruskal–Wallis test: h = 0.91; P = 0.63.
Abbreviation: CBZ, carbamazepine.
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with different genotypes were not statistically significant 
(Table 3).
Our results indicate that the likelihood of a positive 
response to a CBZ monotherapy at an initial dose of 
400 mg is 68%, 44.4%, and 52% in patients with CC, 
CT, and TT genotypes respectively (Figure 2). Patients 
treated with 600 mg, 800 mg, 1000 mg, and 1200 mg 
had the highest likelihood of response if they had the CC 
genotype, followed by the CT and TT genotypes. The 
positive response in the group of patients with CC + CT 
genotypes in comparison with the TT genotype was 
53% versus 52%, 74% versus 60%, 94% versus 84%, 
96% versus 88%, and 100% versus 100%, when treated 
with 400 mg, 600 mg, 800 mg, 1000 mg, and 1200 mg 
daily doses respectively (Figure 3).
The in vivo analysis of expression of the ABCB1 
C3435T variant showed a slightly higher expression of 
the C versus T allele in PBMC, (C/T allele = 48% ± 5%) 
(Figure 4).
The CC genotype was also associated with lower average 
total plasma CBZ levels (23 ± 7.850 µmol/L) in comparison 
with the TT genotype (27.29 ± 6.326 µmol/L) (Figure 5). The 
values for median of total plasma CBZ levels were 20 µmol/L 
for the CC, 23 µmol/L for the CT, and 29 µmol/L for the 
TT genotype.
Discussion
We evaluated the influence of the C3435T as a predictive 
factor for the efficacy of the CBZ therapy in patients with 
epilepsy. Our study demonstrated no differences in allele 
frequency and genotype distribution between patients with 
CBZ-resistant and CBZ-responsive epilepsy, suggesting 
that the variant is not a major factor which influences the 
responsiveness of patients to this drug. Although conflicting 
results were published in several smaller studies,2–5 a recently 
published meta-analysis of 23 studies (7067 patients) indi-
cated no significant association of ABCB1 alleles, genotypes 
and haplotypes with the response to treatment in the over-
all population or in each ethnicity,15 which is in line with 
our findings.
In this study we detected a trend indicating that patients 
with the TT genotype require a higher dose of CBZ in 
comparison with patients with the CT and CC genotypes, 
which was also followed by corresponding differences in 
plasma CBZ levels. These differences did not reach statisti-
cal significance, most probably due to the small number of 
patients in each group. However, the assumption that the 
genotype of the ABCB1 C3435T SNP might be clinically 
relevant was supported by the findings of a higher prob-
ability of response of CC genotype patients in comparison 
with patients with CT and TT genotypes across a wide 
range of doses.
The influence of the ABCB1 C3435T polymorphism on 
Pgp expression and function is still not clear. We detected 
a minor difference (C/T = 48%) in the expression levels 
between the two alleles in peripheral blood mononuclear 
cells of heterozygotes for the variant using a highly sensi-
tive assay that is able to detect differences in expression of 
less than 10% between allelles.16 This difference of ∼5% 
in expression levels in heterozygotes might be translated 
into ∼10% difference in homozygotes for the variant, which 
would explain the trend towards a dose-dependent efficacy 
of a CBZ treatment in patients with different genotypes. 
Whether the differences detected in the expression level 
of ABCB1 in PBMC are accentuated in therapeutically 
more relevant tissues, such as enterocytes, blood–brain 
barrier or nerve cells, is a subject of further evaluation. 
It is also possible, as suggested by Kimchi-Sarfaty et al,17 
that synonymous SNPs have functional effect by affecting 
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Figure 2 Likelihood of a positive response to CBZ therapy between patients with 
different genotypes.
Abbreviation: CBZ, carbamazepine.
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CC + CT genotypes vs TT genotype.
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the timing of cotranslational folding and insertion of Pgp 
into the membrane, thus altering the structure of substrate 
and/or inhibitor interaction sites. However, we cannot 
exclude the possibility that these minor differences are not 
functionally relevant and that there might be another linked 
nonsynonymous SNP in our population that primarily influ-
ences the activity levels of P-glycoprotein. Further studies 
for complete sequencing of the ABCB1 gene as well as 
determination of both mRNA and protein expression lev-
els in patients with different variants from our population 
should clarify this issue.
However, our data suggest that even minor differences 
in expression of a certain variant might result in clinically 
relevant differences in the efficacy of the therapy in patients 
treated with different initial doses of CBZ. A larger prospective 
study designed to address and clarify this issue is warranted.
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